Ireland· IE-PA-EU/1/15/1062/001-004
RAVICTI 1.1 g/ml oral liquid
A glycerol phenylbutyrate product containing glycerol phenylbutyrate, registered in Ireland by Immedica Pharma AB. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Glycerol phenylbutyrate is registered in 13 of 19 countries.
Countries holding a registration under ATC A16AX09 (glycerol phenylbutyrate), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Glycerol phenylbutyrate · ATC A16AX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Glycerol phenylbutyrate
- Manufacturer
- Immedica Pharma AB
- Country
- Ireland (IE)
- ATC code
- A16AX09
- ATC class
- Glycerol phenylbutyrate
- Defined daily dose
- 15 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/15/1062/001-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
244 interactions on record for glycerol phenylbutyrate.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glycerol phenylbutyrate · interactions on record
244 records
- 5 severe
- 235 moderate
- 4 minor
Most severe, free to view
- ProbenecidM04AB01severe
- Valproic acidN03AG01severe
- PantoprazoleA02BC02moderate
- MetoclopramideA03FA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glycerol phenylbutyrate in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United Statesglycerol phenylbutyrateLupin Pharmaceuticals, Inc.
- CzechiaRAVICTIImmedica Pharma AB, Stockholm
- FinlandRAVICTIImmedica Pharma AB
- FranceRAVICTI 1,1 g/ml, liquide oralIMMEDICA PHARMA (SUEDE)
- BelgiumRavicti 1.1 g/mlImmedica Pharma
- PolandRavictiImmedica Pharma AB
- SwedenRAVICTI 1,1 g/ml Oral vätskaImmedica Pharma AB
- IcelandRavictiImmedica Pharma AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ravicti
- Liechtenstein · Ravicti
- Norway · Ravicti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bbdc44f2-7f92-4eeb-8637-6f8a0fd49617 GET /v1/drugs/bbdc44f2-7f92-4eeb-8637-6f8a0fd49617?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral liquid",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A16AX09"
],
"strength": null,
"pa_number": "EU/1/15/1062/001-004",
"substances": [
"Glycerol phenylbutyrate"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "27/11/2015",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about glycerol phenylbutyrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.